Skip to main content
SpringerLink
Log in
Book cover

The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism pp 3–31Cite as

Paraoxonases: An Historical Perspective

  • Chapter

Part of the book series: Proteins And Cell Regulation ((PROR,volume 6))

Abstract

This chapter provides a brief overview of the history of studies on human paraoxonases. It honors the memory of the late Dr. Bert La Du (1920–2005), who with his graduate students, postdoctoral fellows and collaborators made many contributions to our knowledge of this family of enzymes and the genes that encode them. Dr. La Du was honored for these contributions at the First International Conference on Paraoxonases (PONs) – “Paraoxonases: Basic and Clinical Directions of Current Research” held in Ann Arbor, Michigan in 2004. Many of the scientists who trained with and/or collaborated with the late Dr. La Du were present at this Second International Conference on Paraoxonases and have contributed to this volume. This chapter begins with a review of some of the early esterase enzymology and the discovery of plasma paraoxonase activity. The pioneering work of Dr. Norman Aldridge who differentiated the A- and B-esterases is described.

The studies that defined the polymorphic distribution of PON1 in human populations are discussed along with the many different biochemical assays that were developed to explore this interesting polymorphism. The experiments that led to the purification and cloning of human and rabbit PON1s are described along with the properties of this first enzyme know to retain its signal sequences for use in anchoring it into the HDL particle are discussed.

Recent advances by Tawfik and co-workers which include the generation of a PON1 sequence that could be expressed, crystallized and characterized are presented along with the characterization of the many different substrates of this promiscuous enzyme including physiological lactone and xenobiotic lactone substrates. The lactonase activities were characterized by both Tawfik’s team and Dr. La Du’s research group.

The expression and characterization of PON1, PON2 and PON3 by Dr. La Du’s research team is also discussed. This effort along with related work by other research groups has greatly expanded our knowledge of the many different activities of the PON family of enzymes. It is probably appropriate to include these proteins in the antioxidant family of proteins.

The history of the role of the PONs in lipid metabolism and the association of the genetic variability in the PON family of enzymes is discussed. The important take home lesson from understanding the relationship of genetic variability of PON1 and risk for vascular disease was often stressed by Dr. La Du as well as other leaders in PON1 research is that is both the quantity (plasma PON1 level) as well as the quality of PON1 (position 192 genotype) that need to be considered when evaluating risk of disease.

Experiments on the relationship of the genetic variability of PON1 and risk of exposure to organophosphorus compounds are also discussed. The take home message is the same, in some cases the quality of PON1 (Q192R) is important, but in all cases, the quantity of plasma PON1 is important. This consideration holds for all epidemiological studies that examine the relationship of PON genetic variability and disease

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adkins, S., Gan, K.N., Mody, M., and La Du, B.N., 1993, Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191 for the respective A or B allozymes. Am. J. Hum. Genet. 52, 598–608

    CAS  PubMed  Google Scholar 

  • Aharoni, A., Gaidukov, L., Yagur, S., Toker, L., Silman, I., and Tawfik, D.S., 2004, Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci., 101, 482–487

    Article  CAS  PubMed  Google Scholar 

  • Aldridge, W.N., 1953a, Serum esterases I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate and a method for their determination. Biochem J, 53, 110–117

    CAS  Google Scholar 

  • Aldridge, W.N., 1953b, Serum esterases II. An enzyme hydrolysing diethyl p-nitrophenyl acetate (E600) and its identity with the A-esterase of mammalian sera. Biochem. J., 53, 117–124

    CAS  Google Scholar 

  • Atterberry, T.T., Burnett,W.T., and Chambers, J.E., 1997, Age-related differences in parathion and chlorpyrifos toxicity in male rats: target and nontarget esterase sensitivity and cytochrome P450–mediated metabolism. Toxicol. Appl. Pharmacol., 147, 411–418

    Article  CAS  PubMed  Google Scholar 

  • Augustinsson, K.B., and Barr, M., 1963, Age variation in plasma arylesterase activity in children. Clin Chim Acta, 8, 568–573

    Article  CAS  PubMed  Google Scholar 

  • Biggadike, K., Angell, R.M., Burgess, C.M., Farrell, R.M., Hancock, A.P., Harker, A.J., Irving, W.R., Ioannou, C., Procopiou, P.A., Shaw, R.E., Solanke, Y.E., Singh, O.M., Snowden, M.A., Stubbs, R.J., Walton, S., and Weston, H.E., 2000, Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. J. Med. Chem. 43,19–21

    Article  CAS  PubMed  Google Scholar 

  • Blatter, M.C., James, R.W., Messmer, S., Barja, F., and Pometta, D., 1993, Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein: K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211, 871–9

    Article  CAS  PubMed  Google Scholar 

  • Bog-Hansen, T.C., Krog, H.H., and Back, U., 1978, Plasma lipoprotein-associated arylesterase is induced by bacterial lipopolysaccharide. Febs. Lett. 93, 86–90

    Article  CAS  PubMed  Google Scholar 

  • Brophy, V., Jarvik, G.P., and Furlong, C.E., 2002, PON1 Polymorphisms. In: Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects (L.G. Costa and C.E. Furlong, eds.) Kluwer Academic Press, Boston, USA, pp. 53–77

    Google Scholar 

  • Brushia, R.J., Forte, T.M., Oda, M.N., La Du, B.N., and Bielicki, J.K., 2001, Baculovirus-mediated expression and purification of human serum paraoxonase 1A. J. Lipid Res., 42, 951–958

    CAS  PubMed  Google Scholar 

  • Chelur, D.S., Ernstrom, G.G., Goodman, M.B., Yao, C.A., Chen, L., Hagan, R.O., and Chalfie, M., 2002, The mechanosensory protein MEC-6 is a subunit of the C. elegans touch-cell degenerin channel, Nature, 420, 669–673

    Article  CAS  PubMed  Google Scholar 

  • Choi, S.S., and Forster, T.L., 1967a, Triton X-155 as a stabilizer of bovine plasma arylesterase activity. Dairy Sci,, 50, 837–39

    CAS  Google Scholar 

  • Choi, S.S., and Forster, T.L., 1967b, Purification of bovine. plasma arylesterase. J. Dairy Sci., 50, 1088–1091

    Article  CAS  Google Scholar 

  • Clendenning, J.B., Humbert, R., Green, E.D., Wood, C., Traver, D., and Furlong, C.E., 1996, Structural organization of the human PON1 gene. Genomics 35, 586–589

    Article  CAS  PubMed  Google Scholar 

  • Cole, T.B., Jampsa, R.L., Walter, B.,J., Arndt, T.L., Richter, R.J., Shih, D.M., Tward, A., Lusis, A.J., Jack, R.M., Costa, L.G., and Furlong, C.E., 2003, Expression of human paraoxonase (PON1) during development. Pharmacogenetics, 13, 357–364

    Article  CAS  PubMed  Google Scholar 

  • Connelly, P.W., Draganov, D., and Maguire, G.F., 2005, Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite. Free Radic. Biol. Med., 38, 164–74

    Article  CAS  PubMed  Google Scholar 

  • Costa, L.G., and Furlong, C.E. eds., 2002, Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Kluwer Academic Publishers, Boston, USA

    Google Scholar 

  • Costa, L.G., McDonald, B.E., Murphy, S.D., Omenn, G.S., Richter, R.J., Motulsky, A.G., and Furlong, C.E., 1990, Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol. Appl. Pharmacol., 103, 66–76

    Article  CAS  PubMed  Google Scholar 

  • Costa, L.G., Vitalone, A., Cole, T.B., and Furlong, C.E., 2005, Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol., 69, 541–550

    Article  CAS  PubMed  Google Scholar 

  • Davies, H., Richter, R.J., Keifer, M., Broomfield, C., Sowalla, J., and Furlong, C.E., 1996, The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14, 334–336

    Article  CAS  PubMed  Google Scholar 

  • Deakin, S.P., and James, R.W., 2004, Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond), 107, 435–47

    CAS  Google Scholar 

  • Diepgen, T.L., and Geldmacher, V., Mallinkrodt, M., 1986, The human serum paraoxonase polymorphism. Arch. Toxicol. Suppl., 9, 154–158

    CAS  PubMed  Google Scholar 

  • Don, M.M., Masters, C.J., Winzor, D.J., 1975, Further evidence for the concept of bovine plasma arylesterase as a lipoprotein. Biochem. J., 151, 625–630

    CAS  PubMed  Google Scholar 

  • Draganov, D.I., and La Du, B.N., 2004, Pharmacogenetics of paraoxonses, a brief review. Naunyn-Schmiedeberg’s Arch. Pharmacol., 369, 78–88

    Article  CAS  Google Scholar 

  • Draganov, D.I., Stetson, P.L., Watson, C.E., Billecke, S.S., and La Du, B.N., 2000, Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J., Biol., Chem., 275, 33435–33442

    Article  CAS  Google Scholar 

  • Draganov, D.I., Teiber, J.F., Speelman, A., Osawa, Y., Sunahara, R., La Du, B.N., 2005, Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res., 46, 1239–1247

    Article  CAS  PubMed  Google Scholar 

  • Durrington, P.N., Mackness, B., and Mackness, M.I., 2001, Paraoxonase and Atherosclerosis. Atheroscler. Thromb. Vasc. Biol., 21, 473–480

    CAS  Google Scholar 

  • Eckerson, H.W., Wyte, C.M., and La Du, B.N., 1983, The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35, 1126–1138

    CAS  PubMed  Google Scholar 

  • Ecobichon, D.J., and Stephens, D.S., 1973, Perinatal development of human blood esterases, Clin Pharmacol. Ther., 14, 41–47

    CAS  Google Scholar 

  • Furlong, C.E., Richter, R.J., Chapline, C., Crabb, J.W., 1991, Purification of rabbit and human serum paraoxonase. Biochemistry, 30,10133–10140

    Google Scholar 

  • Furlong, C., Holland, N., Richter, R., Bradman, A., Ho. A., and Eskenazi, B., 2006, PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity, Pharmacogenet. Genomics, 16, 183–190

    CAS  Google Scholar 

  • Gan, K., Smolen, A., Eckerson, H.W., La Du, B.N., 1991, Purification of human serum paraoxonase/arylesterase: Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19, 100–106

    CAS  PubMed  Google Scholar 

  • Geldmacher-von Mallinckrodt, M., and Diepgen, T.L., 1988, The human serum paraoxonase polymorphism and specificity. Toxicol. Environ. Chem., 18, 79–196

    CAS  Google Scholar 

  • Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir, H., Ravelli, R.B.G., McCarthy, A., Toker, L., Silman, I., Sussman, J.L, and Tawfik, D.S., 2004, Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol., 11, 412–419

    Article  CAS  PubMed  Google Scholar 

  • Hassett, C., Richter, R.J., Humbert, R., Chapline, C., Crabb, J.W., Omiecinski, C.J., and Furlong, C.E., 1991, Characterization of cDNA clones encoding rabbit and human serum paraoxonase, the mature protein retains its signal sequence. Biochemistry, 30, 10141–10149

    Article  CAS  PubMed  Google Scholar 

  • Humbert, R., Adler, D.A., Disteche, C.M., Hassett, C., Omiecinski, C.J., and Furlong, C.E. 1993, The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet., 3, 73–76

    Article  CAS  PubMed  Google Scholar 

  • Jarvik, G.P., Hatsukami, T.S., Carlson, C.S., Richter, R.J., Jampsa, R., Brophy, V.H., Margolin, S., Rieder, M.J., Nickerson D.A., Schellenberg G.D., Heagerty P.J., and Furlong C.E., 2003a, Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure predicts vascular disease. Arterioscler. Thromb. Vasc. Biol., 23, 1465–1471

    Article  CAS  Google Scholar 

  • Jarvik, G.P., Jampsa, R., Richter, R.J, Carlson, C., Rieder, M., Nickerson, D., and Furlong, C.E., 2003b, Novel Paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics, 13, 291–295

    Article  CAS  Google Scholar 

  • Jarvik, G.P., Rozek, L.S., Brophy, V.H., Hatsukami, T.S., Richter, R.J., Schellenberg, G.D., and Furlong, C.E., 2000, Paraoxonase phenotype is a better predictor of vascular disease than PON1192 or PON155 genotype. Atheroscler. Thromb. Vas.c Biol., 20, 2442–2447

    Google Scholar 

  • Josse, D., Lockridge, O., Xie, W., Bartels, C.F., Schopfer, L.M., and Masson, P., 2001, The active site of human paraoxonase (PON1). J. Appl. Toxicol. Suppl. 1, S7–11

    Article  CAS  Google Scholar 

  • Josse, D., Xie, W., Renault, F., Rochu, D., Schopfer, L.M., Masson, P., and Lockridge, O., 1999, Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities. Biochemistry, 38, 2816–2825

    Article  CAS  PubMed  Google Scholar 

  • Kanagasundaram, V., and Scopes, R., 1992, Isolation and characterization of the gene encoding gluconolactonase from Zymononas mobilis. Biochim. Biophys. Acta, 1171, 198–200

    CAS  PubMed  Google Scholar 

  • Kelso, G.J., Stuart, W.D., Richter, R.J., Furlong, C.E., Jordan-Starck, T.C., and Harmony, J.A., 1994, Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry, 33, 832–839

    Article  CAS  PubMed  Google Scholar 

  • Khersonsky, O., and Tawfik, D.S., 2005, Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry, 44, 6371–6382

    Article  CAS  PubMed  Google Scholar 

  • Kitchen, B.J., Masters, C.J., and Winzor, D.J., 1973, Effects of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase. Biochem. J., 135, 93–99

    CAS  PubMed  Google Scholar 

  • Knowlton, R.G., Cohen-Haguenauer, O., Van Cong, N., Frezal, J., Brown, V.A., Barker, D., Braman, J.C., Schumm, J.W., Tsui, L.C., Buchwald, M., et al., 1985, A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7. Nature, 318, 380–382

    Article  CAS  PubMed  Google Scholar 

  • Kobayashi, M., Shinohara, M., Sakoh, C., Kataoka, M., and Shimizu, S., 1998, Lactone-ring-cleaving enzyme: Genetic analysis, novel RNA editing and evolutionary implications. Proc. Natl. Acad. Sci. USA, 95, 12787–12792

    Article  CAS  PubMed  Google Scholar 

  • Kuo, C.-L., La Du, B.N., 1998, Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug. Metab. Dispos. 26, 653–660

    CAS  PubMed  Google Scholar 

  • La Du, B.N., 1992, Human serum paraoxonase/arylesterase. In, Pharmacogenetics of Drug Metabolism (W. Kalow, ed.) Pergamon Press, New York USA pp. 51–91

    Google Scholar 

  • La Du, B.N., 2002, Historical considerations. In, Paraoxonase (PON1) in Health and Disease, Basic and Clinical Aspects. (L.G. Costa and C.E. Furlong, eds.) Kluwer Academic Press, Boston, USA,. Pp. 53–77

    Google Scholar 

  • La Du, B.N., Adkins, S., Kuo, C.-L., and Lipsig, D., 1993, Studies on human serum paraoxonase/arylesterase, Chem.-Biol. Interact. 87, 25–34

    Article  Google Scholar 

  • Li, W.-F., Costa, L.G., and Furlong, C.E., 1993, Serum paraoxonase status: a major factor in determining resistance to organophosphates. J. Toxicol. Environ. Health, 40, 337–346

    Article  CAS  PubMed  Google Scholar 

  • Li, W.-F., Costa, L.G., and Furlong, C.E., 1997, Paraoxonase (Pon1) gene in mice: sequencing, chromosomal location, and developmental expression. Pharmacogenetics, 7, 137–144

    Article  CAS  PubMed  Google Scholar 

  • Li, W.-F., Costa, L.G., Richter, R.J., Hagen, T., Shih, D.M., Tward, A., Lusis A.J., and Furlong, C.E., 2000, Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphates, Pharmacogenetics, 10, 767–780

    Article  CAS  PubMed  Google Scholar 

  • Li, W.-F., Furlong, C.E., and Costa, L.G., 1995, Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett., 76, 29–226

    Article  Google Scholar 

  • Liu, J., Oliver, K, and Pope, C.N., 1999, Comparative neurochemical effects of repeated methyl parathion or chlorpyrifos exposures in neonatal and adult rats. Toxicol. Appl. Pharmacol. 158, 186–196

    Article  CAS  PubMed  Google Scholar 

  • Lu, H., Zhu, J., Zang, Y., Ze, Y., and Qin, J. 2006, Cloning, purification, and refolding of human paraoxonase-3 expressed in Escherichia coli and its characterization. Protein Expr. Purif., 46, 92–99

    Article  CAS  PubMed  Google Scholar 

  • Mackness, B., Davies, G.K., Turkie, W., Lee, E., Roberts, D.H., Hill, E., Roberts, C., Durrington, P.N., and Mackness, M.I., 2001, Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol.,21, 1451–1457

    Article  CAS  Google Scholar 

  • Mackness, B., Durrington, P.N., and Mackness, M.I., 1998, Human Paraoxonase. Gen Pharmac, 31, 329–336

    Article  CAS  Google Scholar 

  • Mackness, M., Arrol, S., Durrington, P.N., 1991, Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett., 286, 152–154

    Article  CAS  PubMed  Google Scholar 

  • Mackness, M., and Mackness, B., 2004, Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic. Biol. Med., 37, 1317–1323

    CAS  Google Scholar 

  • Mackness, M.I., and Walker, C.H., 1983, Partial purification and properties of sheep serum ‘A’ esterases. Biochem. Pharmacol., 32, 2291–2296

    Article  CAS  PubMed  Google Scholar 

  • Mackness, M.I., and Walker, C.H., 1988, Multiple forms of sheep serum A-esterase activity associated with the high-density lipoprotein. Biochem. J., 250, 539–545

    CAS  PubMed  Google Scholar 

  • Main, A.R., 1956, The role of A-esterase in the acute toxicity of paraoxon, TEEP and parathion. Can. J. Biochem. Physiol., 34, 197–216

    CAS  PubMed  Google Scholar 

  • Main, A.R., 1960, The purification of the enzyme hydrolysing diethyl-p-nitrophenyl phosphate (paraoxon) in sheep serum. Biochem. J., 74,10–20

    CAS  PubMed  Google Scholar 

  • Mazur, A., 1946, An enzyme in animal tissue capable of hydrolyzing the phosphorus-fluorine bond of alkyl fluorophosphates. J. Biol. Chem., 164,271–289

    CAS  Google Scholar 

  • Mochizuki, H., Scherer, S.W., Xi, T., Nickle, D.C., Majer, M., Huizenga, J.J., Tsui, L.C., and Prochazka, M., 1998, Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene, 213(1–2), 149–157

    Article  CAS  PubMed  Google Scholar 

  • Moser, V.C., Chanda, S.M., Mortensen, S., and Padilla, S., 1998, Age and gender-related differences in sensitivity to chlorpyrifos in the rat reflect developmental profiles of esterase activity, Toxicol. Sci., 46, 211–222

    CAS  Google Scholar 

  • Ng, C.J., Shih, D.M., Hama, S.Y., Villa, B., Navab, M., and Reddy, S.T., 2005, The paraoxonase gene family and atherosclerosis, Free Radic. Biol. Med., 38, 153–163

    Article  CAS  PubMed  Google Scholar 

  • Ohbu, S., Yamashina, A., Takasu, N., Yamaguchi, T., Murai, T., Nakano, K., Matsui, Y., Mikami, R., Sakurai, K., and Hinohara, S., 1997, Sarin poisoning on Tokyo subway. South. Med. J., 90, 587–593

    CAS  PubMed  Google Scholar 

  • Ortigoza-Ferado, J., Richter, R., Hornung, S.K., Motulsky, A.G., and Furlong, C.E., 1984, Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin. Am. J. Hum. Genet. 36,295–305

    CAS  PubMed  Google Scholar 

  • Ozer, E.A., Pezzulo, A., Shih, D.M., Chun, C., Furlong, C., Lusis, A.J., Greenberg, E.P., and Zabner, J., 2005, Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing, FEMS Microbiol. Lett., 253, 29–37

    CAS  Google Scholar 

  • Ozols, J., 1999, Isolation and complete covalent structure of liver microsomal paraoxonase. Biochem. J. 338,265–272

    Article  CAS  PubMed  Google Scholar 

  • Primo-Parmo, S.L., Sorenson, R.C., Teiber, J., and La Du, B.N., 1996, The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics, 33, 498–507

    Article  CAS  PubMed  Google Scholar 

  • Richter, R.J., and Furlong, C.E., 1999, Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics, 9, 745–753

    Article  CAS  PubMed  Google Scholar 

  • Richter, R.J., Jampsa, R.L., Jarvik, G.P., Costa, L.G., and Furlong, C.E, 2004, Determination of paraoxonase 1 (PON1) status and genotypes at specific polymorphic sites, In Current Protocols in Toxicology, MD Mains, LG Costa, DJ Reed, E Hodgson, eds., John Wiley and Sons, New York, NY. Pp. 4.12.1–4.12.a19.

    Google Scholar 

  • Rochu, D., Chabriere, E., and Masson, P., 2007, Human paraoxonase: A promising approach for pre-treatment and therapy of organophosphorus poisoning, Toxicol., 233, 47–59

    Article  CAS  Google Scholar 

  • Rodrigo, L., Gil, F., Hernandez, A.F., Lopez, O., and Pla, A., 2003, Identification of paraoxonase 3 in rat liver microsomes: purification and biochemical properties, Biochem. J., 376(Pt 1), 261–268

    Article  CAS  PubMed  Google Scholar 

  • Rosenblat, M., Draganov, D., Watson, C.E., Bisgaier, C.L., La Du, B.N., Aviram, M., 2003, Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler. Thromb. Vasc. Biol., 23, 468–474

    Google Scholar 

  • Schmiegelow, K., Eiberg, H., Tsui, L.C., Buchwald, M., Phelan, P.D., Williamson, R., Warwick, W., Niebuhr, E., Mohr, J., Schwartz, M., et al., 1986, Linkage between the loci for cystic fibrosis and paraoxonase. Clin. Genet. 29, 374–377

    Article  CAS  PubMed  Google Scholar 

  • Shih, D.M., Gu, L., Xia, Y.-R., Navab, M., Li, W.-F., Hama, S., Castellani, L.W., Furlong, C.E., Costa, L.G., Fogelman, A.M., and Lusis, A.J., 1998, Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284–287

    Article  CAS  PubMed  Google Scholar 

  • Shiner, M., Fuhrman, B., and Aviram, M., 2004, Paraoxonase 2 (PON2) expression is upregulated via a reduced-nicotinamide-adenine-dinucleotide-phosphate (NADPH)-oxidase-dependent mechanism during monocytes differentiation into macrophages. Free Radic. Biol. Med., 37, 2052–2063

    Article  CAS  PubMed  Google Scholar 

  • Shiner, M., Fuhrman, B., and Aviram, M., 2007, Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic anti-oxidants via PPARgamma and AP-1 pathway activation, Atherosclerosis, 2007 Feb 9; [Epub ahead of print]

    Google Scholar 

  • Skarnes R.C., 1968, In vivo interaction of endotoxin with a plasma lipoprotein having esterase activity. J Bacteriol. 95, 2031–2034

    CAS  PubMed  Google Scholar 

  • Sorenson, R.C., Bisgaier, C.L., Aviram, M., Hsu, C., Billecke, S., and La Du, B.N. 1999, Human serum Paraoxonase/Arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 19, 2214–2225

    CAS  PubMed  Google Scholar 

  • Stoltz, D.A., Ozer, E.A., Ng, C.J., Yu, J., Reddy, S.T., Lusis, A.J., Bourquard, N., Parsek, M.R., Zabner, J., and Shih, D.M., 2006, Paraoxonase-2 Deficiency Enhances Pseudomonas aeruginosa Quorum Sensing in Murine Tracheal Epithelia, Am. J Physiol. Lung. Cell Mol.Physiol., November 22 doi:10.1152/ajplung.00370.2006, 1–43

    Google Scholar 

  • Suzuki, T., Morita, H., Ono, K., Maekawa, K., Nagai, R., and Yazaki, Y., 1995, Sarin poisoning in Tokyo subway. Lancet, 345, 980

    Google Scholar 

  • Teiber, J.F., Draganov, D.I., and La Du, B.N., 2003, Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem. Pharmacol., 66, 887–896

    Article  CAS  PubMed  Google Scholar 

  • Tougou, K., Nakamura, A., Watanabe, S. Okuyama, Y., and Morino, A., 1998, Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441): a prodrug of a new antibacterial agent Drug Metab. Dispos., 26, 355–359

    CAS  Google Scholar 

  • Uriel, J., 1961, Characterization of cholinesterase and other carboxylic esterases after electrophoresis and immunoelectrophoresis on agar. I. Application to the study of esterases of normal human serum. Ann Inst Pasteur (Paris), 101, 104–119

    CAS  Google Scholar 

  • van Himbergen, T.M., van Tits, L.J.H., Roest, M., and Stalenhoef, A.F.H., 2006, The story of PON1: how an organophosphate-hydrolyzing enzyme is becoming a player in cardiovascular medicine. Neth. J. Med., 64, 34–38

    PubMed  Google Scholar 

  • Wainwright, B.J., Scambler, P.J., Schmidtke, J., Watson, E.A., Law, H.Y., Farrall, M., Cooke, H.J., Eiberg, H., and Williamson, R., 1985, Localization of cystic fibrosis to human chromosome 7cen-q22. Nature, 318, 384–385

    Article  CAS  PubMed  Google Scholar 

  • Watson, A., Berliner, J.A., Hama, S.Y., La Du, B.N., Faull, K.F., Fogelman, A.M., and Navab, M., 1995, Protective effect of high density lipoprotein associated paraoxonase – inhibition of the biological activity of minimally oxidized low-density lipoprotein. J. Clin. Invest., 96, 2882–2891

    Article  CAS  PubMed  Google Scholar 

  • Wheeler, J.G., Keavney, B.D., Watkins, H., Collins, R., and Danesh, J., 2004, Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies, Lancet, 363, 689–9

    Article  CAS  PubMed  Google Scholar 

  • White, R., Woodward, S., Leppert, M., O’Connell, P., Hoff, M., Herbst, J., Lalouel, J.M., Dean, M., and Vande Woude, G., 1985, A closely linked genetic marker for cystic fibrosis. Nature, 318, 382–384

    Article  CAS  PubMed  Google Scholar 

  • Wilde, C.E., and Kekwick, R.G.O., 1964, The arylesterases of human serum. Biochem. J., 91, 297–307

    CAS  PubMed  Google Scholar 

  • Yamada, Y., Takatori, T., Nagao, M., Iwase, H., Kuroda, N., Yanagida, J., and Shinozuka, T., 2001, Expression of paraoxonase isoform did not confer protection from acute sarin poisoning in the Tokyo subway terrorist attack. Int. J. Legal Med., 115, 82–84

    Article  CAS  PubMed  Google Scholar 

  • Zech, R., and Zurcher, K., 1974, Organophosphate splitting serum enzymes in different mammals. Comp. Biochem. Physiol., 48B, 427–433

    Google Scholar 

  • Zhu, J., Ze, Y., Zhang, C., Zang, Y., Lu, H., Chu, P., Sun, M., and Qin, J., 2006, High-level expression of recombinant human paraoxonase 1 Q in silkworm larvae (Bombyx mori). Appl. Microbiol. Biotechnol., 72,103–108

    Article  CAS  PubMed  Google Scholar 

  • Zimmerman, J.K., Grothusen, J.R., Bryson, P.K., and Brown, T.M., 1989, Partial purification and characterization of paraoxonase from rabbit serum, In: Enzymes Hydrolysing Organophosphorus Compounds. E. Reiner, W.N. Aldridge, F.C.G. Haskin, eds., Ellis Horwood Ltd., Chichester: pp. 128–142

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine (Div. Medical Genetics) and Genome Sciences, University of Washington, Seattle, WA 98195, USA

    C.E. Furlong

Authors
  1. C.E. Furlong
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Manchester, U.K

    Bharti Mackness

  2. University of Manchester, U.K

    Mike Mackness

  3. Technion Faculty of Medicine, Haifa, Israel

    Michael Aviram

  4. University of Debrecen, Hungary

    György Paragh

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer

About this chapter

Cite this chapter

Furlong, C. (2008). Paraoxonases: An Historical Perspective. In: Mackness, B., Mackness, M., Aviram, M., Paragh, G. (eds) The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism. Proteins And Cell Regulation, vol 6. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6561-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4020-6561-3_1

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-6560-6

  • Online ISBN: 978-1-4020-6561-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation